Clavacillin (amoxicillin trihydrate/clavulanate potassium) is an orally administered formulation comprised of the broad-spectrum antibiotic amoxicillin trihydrate and the £]-lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid).
Amoxicillin trihydrate is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative, aerobic and anaerobic microorganisms. It does not resist destruction by £]-lactamases; therefore, it is not effective against £]-lactamase-producing bacteria. Chemically, it is D(-)-£\-amino-p-hydroxybenzyl penicillin trihydrate
Clavulanic acid, an inhibitor of £]-lactamase enzymes, is produced by the fermentation of Streptomyces clavuligerus. Clavulanic acid by itself has only weak antibacterial activity. Chemically, clavulanate potassium is potassium z-(3R,5R)-2-£]-hydroxyethylidene clavam-3-carboxylate.
Clavacillin Veterinary Tablets (amoxicillin trihydrate/clavulanate potassium) are indicated in the treatment of:
Skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: B-lactamase-producing Staphylococcus aureus, non-?-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. Amoxicillin trihydrate/clavulanate potassium has been shown to be clinically effective for treating cases of canine periodontal disease.
Skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: B-lactamase-producing Staphylococcus aureus, non-?-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli. See package insert for complete product details.
Amoxicillin trihydrate, clavulanate potassium
The recommended dosage is 6.25 mg/lb of body weight twice a day. Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5-7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.
The recommended dosage is 62.5 mg twice a day. Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5-7 days or for 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated. Urinary tract infections may require treatment for 10-14 days or longer. The maximum duration of treatment should not exceed 30 days.
Store at controlled room temperature, 68-77°F (20-25°C). Do not remove from foil strip until ready to use.
The use of this drug is contraindicated in animals with a history of an allergic reaction to any of the penicillins or cephalosporins.
Safety of use in pregnant or breeding animals has not been determined.
Clavacillin contains a semisynthetic penicillin (amoxicillin) and has the potential for producing allergic reactions. If an allergic reaction occurs, administer epinephrine and/or steroids.
To report suspected adverse events, for technical assistance or to obtain a copy of the safety data sheet (SDS), contact Dechra at (866) 933-2472. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or https://www.fda.gov/AnimalVeterinary/SafetyHealth